Enliven Therapeutics (ELVN) Treasury Shares (2022 - 2026)

Enliven Therapeutics has disclosed Treasury Shares across 5 years of filings, most recently posting $323008.0 for Q1 2026.

• Treasury Shares for Q1 2026 came in at $323008.0, up 233.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $323008.0 (up 233.72% YoY), and the FY2025 annual result was $76973.0, up 1.09% from the prior year.
• Treasury Shares came in at $323008.0 for Q1 2026 at Enliven Therapeutics, up from $76973.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $425289.0 in Q1 2022 to a low of $17250.0 in Q3 2023.
• The 5-year median for Treasury Shares is $91251.0 (2024), against an average of $129134.2.
• Across the five-year window, Treasury Shares tumbled 91.92% in 2023 and jumped 435.17% in 2024, its largest moves.
• Enliven Therapeutics' Treasury Shares stood at $213443.0 in 2022, then tumbled by 63.22% to $78505.0 in 2023, then declined by 3.01% to $76145.0 in 2024, then grew by 1.09% to $76973.0 in 2025, then jumped by 319.64% to $323008.0 in 2026.
• The last three Treasury Shares figures came in at $323008.0 (Q1 2026), $76973.0 (Q4 2025), and $83577.0 (Q3 2025), per Business Quant data.